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1.  INTRODUCTION 
1.1. Tuberculosis 1,2,3,4   
Tuberculosis (TB) is an airborne, chronic, deadly bacterial infection caused by   
Mycobacterium tuberculosis (MTB), an aerobic bacilli belonging to the family 
Mycobacteriaceae, first identified in 1882 by Robert Koch, which affects the lungs and other 
organs as well. 
 
Need For Focus on Tuberculosis Disease: 
        The sixteenth global report on tuberculosis by WHO (published in 2011) says  
 In 2010, there were 8.8 million (range, 8.5–9.2 million) incident cases of TB, 1.1 million 
(range, 0.9–1.2 million) deaths from TB among HIV-negative people and an additional 
0.35 million (range, 0.32–0.39 million) deaths from HIV-associated TB. 
 
 In 2009 there were almost 10 million children who were orphans as a result of parental 
deaths caused by TB. 
 
 TB kills four people every minute some-where in the world and accounts about two 
million deaths per year. 
 
 There were 3.2 million (range, 3.0–3.5 million) incident cases of TB and 0.32 million 
(range, 0.20–44 million) deaths from TB among women in 2010. 
 
 About 13% of TB cases occur among people living with HIV. 
 
 Total of 225 million new cases and 79 million deaths are expected from tuberculosis for 
the period between 1998 and 2030.  
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 Approximately 50% of India’s population is reported to be tuberculin test positive.  
 
Need for the New Target 
 
 There is also an alarming increase in cases of  TB caused by Multi-Drug Resistant 
(MDR-TB) strains, Extreme-Drug resistant (XDR-TB) strains and Total Drug Resistance 
(TDR-TB) strains  of Mycobacterium tuberculosis (Mtb), due to inadequate drug therapy 
as a result of incorrectly selected medications (or) suboptimal drug dosing. 
 
 Further Mycobacterium tuberculosis (Mtb) has been exacerbated by human immuno-
deficiency virus (HIV) and their calamitous synergism, since both are destructive 
together than individually. 
 
  Approximately 75-80% of HIV infected patients are co-infected with Mycobacterium 
tuberculosis (Mtb) and as a result 50-70% of HIV positive patients develop active TB. 
Thus TB is predominately a disease of the poor and we must be able to scale up the new 
strategies for combating the problem of TB treatment. 
 
 The HIV epidemic will increase tuberculosis cases by at least 200,000 each year in 
India. If HIV spreads more rapidly, tuberculosis may become uncontrollable for a 
generation.  
 
 Despite enormous efforts taken, no new drug has been introduced in the market for the 
past 40 years and almost all the drugs used for TB and combination therapy have also 
failed in many cases due to tolerance.  
 
 The re-emergence of tuberculosis (TB) as a global health problem over the past few 
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decades, accompanied by the rise of drug-resistant strains of Mycobacterium 
tuberculosis, emphasizes the need for discovery of new therapeutic drugs acting on the 
new targets against this disease.  
All these factors prompted us to search for new targets and new molecules as anti TB agents. 
1.2.   Medicinal Chemistry 5,6,7 
Medicinal chemistry is a discipline at the intersection of Chemistry and Pharmacology 
which involves design, drug synthesis and evaluation of pharmaceutical agents. The drug 
discovery process involves design, synthesize, characterization and evaluation of new chemical 
entities suitable for therapeutic use. It also includes the study of existing drugs, their biological 
properties and their quantitative structure activity relationship (QSAR). 
Drug Discovery 
Drug discovery is the identification of novel active compounds, often called "hits", which 
are typically screened to have desired biological activity on a particular target. They might be 
single or combinations of compounds (compound library). Sources of hits can come from natural 
sources, such as plants, animals, or fungi and also from synthetic chemical libraries, such as 
those created through combinatorial chemistry or historic chemical compound collections that 
are tested en-masse against the biological target in question. 
Optimization 
Next step in drug discovery involves further chemical modifications of the chemical 
entities in order to improve the biological and physiochemical properties of a given compound 
library. Chemical modifications can improve the recognition of binding site (selectivity) and 
binding geometries (Pharmacophores) of the candidate compounds, their affinities and 
pharmacokinetics, or indeed their reactivity and stability during their metabolic degradation, 
which exhibit maximum potency, most selectivity, best pharmacokinetics and least toxicity. This 
step improves Pharmacokinetic and Pharmacodynamic aspects of the compound library which is 
taken for further processes.  
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QSAR study involves mainly physical, chemical and molecular docking tools (CoMFA® 
and CoMSIA®), of compounds that gives the data in first and second order equations. There are 
many theories related to this and the most relevant being Hansch's analysis that involves 
Hammett electronic parameters, steric parameters and logP (lipophilicity) parameters as the basis 
for insilico drug design.  
 1.3 Drug Design 8,9,10  
Drug design is the inventive process of finding new medications based on the knowledge 
of the biological target. The drug is most commonly an organic small molecule which activates 
or inhibits the function of a biological target such as a protein or enzyme, which in turn results in 
a therapeutic benefit to the patient. In the most basic sense, drug design involves design of small 
molecules that are complementary in shape and charge to the biomolecular target to which they 
interact and therefore will bind to it. Drug design frequently but not necessarily relies on 
computer modeling techniques to identify a lead or an active molecule. This type of modeling is 
often referred to as Computer-Aided Drug Design (CADD) or in-silico process. 
Hit identification – Docking combined with scoring function can be used to quickly screen large 
databases of potential drugs in silico to identify molecules that are quickly to bind to protein 
target of interest.    
Lead optimization – Docking can be used to predict orientation of a ligand binding to a protein 
(also referred as binding mode or pose) which is used to design more potent and selective 
analogs.  
Ligand or Guest - The complementary parent molecule which binds to the receptor. Ligands are 
most often small molecules, but could also be another biopolymer.  
Receptor or host - The “receiving” molecule, most commonly a protein or other biopolymer. 
Docking – Computational simulation of a candidate ligand binding to a receptor.  
Binding Mode - The orientation of the ligand relative to the receptor as well as the conformation 
of the ligand and receptor, when bound to each other.  
Pose- A candidate scoring mode.  
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Scoring- The process of evaluation of a particular pose by counting the number of favorable 
intermolecular interactions such as hydrogen bonds and hydrophobic contacts.  
Ranking – The process of classifying which ligands are most likely to interact favorably to a 
particular receptor based on the predicted free energy of binding.  
 
1.3.1 Types 
There are two major types of drug design.  
1. Ligand-based drug design 
2. Structure-Based Drug Design (SBDD).  
Ligand based drug design (Pharmacophore modeling) 
Ligand-based drug design (or indirect drug design) relies on knowledge of other 
molecules that bind to the biological target of interest. These other molecules may be used to 
derive a pharmacophore model which defines the minimum necessary structural characteristics a 
molecule must possess in order to bind to the target. In other words, a model of the biological 
target may be built based on the knowledge of what binds to it and this model in turn may be 
used to design new molecular entities that interact with the target. Alternatively, a Quantitative 
Structure-Activity Relationship (QSAR) in which a correlation between calculated properties of 
molecules and their experimentally determined biological activity may be derived. These QSAR 
relationships in turn may be used to predict the activity of new analogs. 
Pharmacophore model can be developed in two ways by using HIPHOP and HYPOGEN. 
HIPHOP provides feature based alignment without considering activity where as HYPOGEN 
generates activity based pharmacophore model which can predict the activity of new compounds. 
To run a HYPOGEN we need large number (more than 15) of molecule with known activity but 
we have very few molecules to inhibit Thymidylate syntheses (ThyX) of Mycobacterium 
tuberculosis. So we resorted to HIPHOP modeling to suggest the possible alignment of active 
molecules which can generate a pharmacophore model in early stages of project from only a 
small set of compounds of known or unknown activities.  
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Structure based Drug Design (Molecular docking) 
Structure-based drug design (or direct drug design) relies on knowledge of the three 
dimensional structure of the biological target obtained through X-ray crystallography or NMR 
spectroscopy. Structural features of the target allow us to design a drug candidate with suitable 
physiochemical properties necessary for the interaction with the biomolecule.  If an experimental 
structure of a target is not available, then also it is possible to create a homology model of the 
target protein based on the experimental structure of an available related protein. Using the 
structure of the biological target, candidate drugs that are predicted to bind with high affinity and 
selectivity to the target may be designed using interactive graphics and the intuition of a 
medicinal chemist. Alternatively various automated computational procedures also used to 
suggest new drug candidates. 
1.3.2 Docking  
Docking is frequently used to predict the binding orientation of drug candidates to their 
protein targets in order to predict the affinity and activity of the small molecule. Glide is a ligand 
docking program that predicts the protein-ligand binding modes and ranking the ligands via 
high-throughput virtual screening. Glide utilizes two different scoring functions called Standard 
Precision (SP) mode and Extra Precision (XP) mode Glide scores, to rank order the compounds 
based on the interaction with the receptor. Different sampling ligand conformational and 
positional degrees of freedom are available to determine the optimal ligand orientation relative to 
rigid protein receptor geometry.  
The quality of any docking results depends on reasonable starting structures for both the 
protein and the ligand. The protein and ligand structures need to be prepared to achieve the best 
docking results. Following steps are involved in docking process.  
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Protein and preparation 
A typical PDB (Protein Data Bank) structure file can be multimeric consists of heavy 
atoms and can contain waters, cofactors and metal ions. The structure generally has no 
information on bond orders, topologies, or formal atomic charges. Terminal amide groups can 
also be misaligned, because the X-ray structure analysis cannot usually distinguish between       
O and NH2. Ionization and tautomeric states are also generally unassigned. 
The following processes are necessary to make protein to perfect structure for docking 
study: 
1. Assign ionization and tautomeric states of protein properly. (Side chains are reoriented when 
necessary and steric clashes are relieved). 
2. Delete all water molecules (except those coordinated to metals, if water molecules are kept, 
hydrogen’s will be added to them).  
3. Adjust the protonation of the protein, which is crucial when the receptor site is a 
metalloprotein.  
4. Finally minimize the protein to reorient side-chain hydroxyl groups and alleviate potential 
steric clashes present in the PDB structure.  
Ligand Preparation 
To give the best results, the structures that are docked must be good representations of the 
actual ligand structures as they would appear in a protein-ligand complex. Most of the docking 
tools modify the torsional internal coordinates of the ligand during docking, so the rest of the 
geometric parameters must be optimized beforehand.  
               This means that the structures supplied to docking tool must meet the following 
conditions: 
1. They must be three-dimensional (3D).  
2. They must have realistic bond lengths and bond angles.  
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3. They must each consist of a single molecule that has no covalent bonds to the receptor, with 
no accompanying fragments, such as counter ions and solvent molecules.  
4. They must have all their hydrogen’s valences filled.  
5. They must have an appropriate protonation state for physiological pH values.  
Receptor grid generation 
Position and size of binding site in the receptor was represented in this step. Ligand 
docking cannot be performed until the receptor grids have been generated. This process was 
done by the tool (Receptor Gride generation) of maestro 9.1, after the protein preparation 
process.  
 Ligand Docking 
The docking process calculates the binding energies of a particular conformational 
sample ligand with the receptor. Accessing the affinity of various ligands with the particular 
receptor was carried out by Glide by extra precision mode (XP). 
1.3.3 Binding Site Analysis 
Understanding the structure and function of protein binding sites is the cornerstone of 
structure-based drug design and this requires knowledge of both the location and physical 
properties of the binding site. In addition, the identification of small-molecule binding sites as 
modulators of protein-protein interactions is of increasing interest. Furthermore, even when a 
validated binding site has been identified, it is often important to find additional potential 
binding sites where appropriate targeting could result in different biological effects or new 
classes of compounds. When the binding site is not known from a 3-D structure or from other 
experimental data, computational methods can be employed to suggest likely locations. 
Medicinal chemistry efforts to give better ligands in case of receptor with well known binding 
site. Critical assessment of degree to which the occupancy of accessible but unexplored regions 
of receptor binding site for the interaction with ligand can be promoted by improving the 
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physical properties of the ligand. Such assessments can assist in the evaluation and optimization 
both of known binding molecules and of virtual screening hits. It is also important to understand 
the potential drugs ability of the site.  
1.3.4 Scoring Methods 11 
Scoring of docked poses is still regarded as one of the major challenges in the field of 
molecular docking. The purpose of the scoring procedure is the identification of the correct 
binding pose by its lowest energy value and the ranking of protein-ligand complexes according 
to their binding affinities. Scoring functions can be divided in empirical scoring functions, 
scoring functions derived from force fields and knowledge-based scoring functions. Scoring 
functions derived from force fields handle the ligand binding prediction with the use of potential 
energies (non-bonded interaction terms) and sometimes in combination with solvations and 
entropy contributions. Knowledge-based scoring functions are based on atom pair potentials 
derived from structural databases. Forces and potentials are collected from known protein-ligand 
complexes to get a score for their binding affinities. 
1.4 Scope  
Today, CADD and screening methods have become the basis of new drug discovery.  As 
the computational technologies advance there is increased efficiency of the drug discovery 
processes, minimized time duration and resource needs. In addition, as the knowledge of 
structural information of potential therapeutic targets dramatically expands, it drives the 
development of the new computational methodologies with greater automation, faster algorithms 
and improved information management techniques. On a genomic scale, instead of looking at 
individual targets, families of related targets will be studied. The information available on ligand 
binding to these families will be vastly expanded and used for discovery process. 
          The job of the molecular modeler is to handle the data effectively, as well as translate the 
available structural information into a form directly usable by the bench chemist. This mission 
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will ultimately cause a greater interface of bio and chemoinformatics, leading to improved 
structural and functional genomics knowledge. 
 1.5 Absorption, Distribution, Metabolism, Excretion (ADME) Analysis 
Usually drug discovery and development are expensive and time-consuming processes. 
In pharmaceutical research many new drug failures which occur in the phase of clinical trials are 
due to ADME properties. This has to be identified early in the drug discovery process. Thus, in-
vitro approaches are now widely used to investigate the ADME properties of new chemical 
entities and more recently, computational (in silico) modeling has been investigated as a tool to 
optimize selection of the most suitable drug candidates for development. 
The objective of in-silico modeling tools for predicting these pharmacokinetic properties 
is to serve two key aims. First, at the design stage of new compounds and compound libraries so 
as to reduce the risk of late-stage attrition; and second, to optimize the screening and testing by 
looking at only the most promising active compounds. 
 Lipinski‘s rule-of-five: The properties which can differentiate drugs from other 
chemicals can be considered as drug like properties. The crucial properties of the chemical 
candidate for oral delivery (Lipinski‘s rule-of-five) includes molecular mass <500 Daltons (Da), 
calculated octanol / water partition coefficient (CLOGP) <5, number of hydrogen-bond donors 
<5 and number of hydrogen-bond acceptors <10. These properties are then typically used to 
predict ADME models and form the basis for what has been called property-based drug design. 
A deeper understanding of the relationships between ADME parameters with molecular 
structure properties has been used to develop in silico models that allow the early estimation of 
several ADME properties of the newer candidates. Among other important issues, prediction of 
properties that provide information about dose size and dose frequency such as oral absorption, 
bioavailability, brain penetration, clearance (for exposure) and volume of distribution are (for 
frequency) also needed for such drugs.  
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Prediction of ADME and related properties 
Absorption: For a compound crossing a biological membrane by purely passive 
diffusion, a reasonable permeability estimate can be made using single molecular property, such 
as log D (Diffusion coefficient) or hydrogen-bonding capacity. The simplest insilico model for 
estimating absorption are based on a single descriptor, such as log P (Partition coefficient) or log 
D, or polar surface area, which is a descriptor of hydrogen-bonding potential. Different 
multivariate approaches, such as multiple linear regressions, partial least squares and artificial 
neural networks, have been used to predict quantitative structure–human-intestinal-absorption 
relationships. 
Bioavailability: Important properties for determining permeability (Bioavailability) seem 
to be the size of the molecule, its capacity to make hydrogen bonds, its overall lipophilicity, its 
shape and flexibility. 
Blood–brain barrier penetration: (BBB) Drugs to act in the CNS need to cross the 
blood–brain barrier (BBB) to reach their molecular target in the brain. By contrast, for drugs 
with a peripheral target, BBB penetration might not be required in order to avoid CNS side 
effects. Lipinski rule-of-five recommendations regarding the molecular parameters that 
contribute to the ability of molecules to cross the BBB have been made to aid BBB-penetration 
predictions. 
 Example: molecules with a molecular mass of <450 Da or with Polar surface area 
(PSA) <100 Å are more likely to penetrate the BBB along with other drug like parameters.  
Dermal and ocular penetration: The existing octanol/water partition coefficient models 
are typically a function to estimate aqueous solubility, including hydrogen-bonding parameters, 
molecular weight and molecular flexibility. Insilico commercial models for the prediction solute-
permeation rates through the skin are available, like the QikProp and DermWin programs. 
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Metabolism: In silico approaches also available to predict metabolism can be divided into 
QSAR and three-dimensional- QSAR studies, protein and pharmacophore models and predictive 
databases. Predictive-metabolism tools currently used require considerable input from a 
computational chemist and some other tools also be used as rapid filters for the screening of 
virtual libraries. Perhaps the most intellectually used and satisfying molecular modeling studies 
are those based on the crystal structure of the metabolizing enzymes. Several approaches that use 
databases to predict metabolism are available. Ultimately, such programs might be linked to 
computer-aided toxicity prediction on the basis of quantitative structure–toxicity relationships 
and expert systems for toxicity evaluation. 
1.6 In silico prediction of toxicity issues 
Toxicity is responsible for ~20–40% of drug failures to reach the market and for the 
withdrawal of a significant number of compounds from the market once they have been 
approved. Commercially in-silico tools are available and can be used for forecasting potential 
toxicity issues, they were roughly classified into two groups. The first approach uses expert 
systems that derive models on the basis of abstracting and codifying knowledge from human and 
the scientific literature sources. The second approach relies on the generation of descriptors of 
chemical structure and statistical analysis of the relationships between these descriptors and the 
toxicological end-point. 
Current software packages are primarily emphasis on carcinogenicity and mutagenicity, 
although some packages do also include tools and/or knowledge bases for other end-points, such 
as teratogenicity, irritation, sensitization, immunotoxicology and neurotoxicity. There is an 
unmet need for in-silico predictive toxicology software for other end-points important in drug 
development, such as QT prolongation hepatotoxicity and phospholipidosis. 
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1.7 ANTITUBERCULAR ACTIVITY 
In-vitro methods are laboratory experiments which are used as a confirmatory tool for the 
synthesized compounds. Every synthesized chemical entity should be evaluated in-vitro and in-
vivo for the conformation of the expected activity.  
In-Vitro assays  
 MB 7H10 Agar dilution Assay  
  Micro plate Alamar Blue Assay (MABA) 
 Resazurin Microtitre Assay (REMA ) 
  Luciferase Reporter Phage Assay (LRP) 
 Serine/Threonine Protein (STP)  Kinase Assay 
 BACTEC-TB system 
 
In-vivo assays 
 Balb/C mouse model for CFU and mortality.  
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1.8 Toxicological Evaluation 
Principle and Purposes 
Acute toxicity tests the toxicity of a chemical or a drug substance after a single oral 
administration.  
The main purpose of this study is to evaluate the degrees of toxicity in a quantitative and 
qualitative manner to compare it with the existing drug candidates. Further acute toxicity study 
provides the information about the acute toxicity effects of a chemical in a quantitative manner 
i.e. it gives information about the mechanism of acute toxicity.  
   The method of evaluation has been changed in the last three decades mainly for animal 
welfare reasons. Producing mortality in animals in order to determine LD50 (dosis letalis media) 
is no longer the main purpose of acute toxicity study. Nowadays acute toxicity study mainly 
focuses on acute tolerance, nature of acute toxicity, symptoms in sub-lethal range and dose levels 
which acute mortality in few animals. i.e quality has replaced quantity.  
The test is based on stepwise procedure with use of minimum number of animals per 
step, sufficient information is obtained on the acute toxicity of the test substance to enable its 
classification.  
The drug substance is administered orally to a group of experimental animals at one of the 
defined dose. The drug is tested using a stepwise procedure, each step using three animals of a 
single sex (normally females). Absence or presence of compound-related mortality of the 
animals dosed at one step will determine the next step i.e. 
 No further testing is needed  
 Dosing of three additional animals, with same dose, 
 Dosing of three additional animals at the next higher or the next lower dose levels. 
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Literature Review 
The literature was reviewed to gain insight about the disease, drug design of ligands, 
synthesis, characterization, and methods of invitro evaluation.   
Drug design  
1. Damien Leduc et al., 11 (2007) Thymidylate Synthase (ThyX) role in de nova folate 
synthetic pathway in microorganism were established. Flavin-dependent ThyX proteins 
show thymidylate synthase activity in vitro and functionally complement ThyA defects 
in heterologous systems, direct proof of their cellular functions is missing.    
 
2. Eric M. Koehn et al., 12 (2009) Thymidylate biosynthesis pathway in ThyX gene 
containing micro organism were characterized. Biosynthesis of the DNA base thymine 
depends on activity of the enzyme Thymidylate Synthase (TS) to catalyze the 
methylation of the uracil moiety of 2’-deoxyuridine-5’-monophosphate (dUMP).  
known Thymidylate Synthases (TSs) rely on an active site residue of the enzyme to 
activate dUMP1.  
 
3. Damien Leduc et al., 13 (2004) Acting binding site in the Thymidylate Synthase (ThyX) 
was established.  Identified several residues of the Helicobacter pylori ThyX protein 
with crucial roles in ThyX catalysis. By providing functional evidence that the active 
site(s) of homotetrameric ThyX proteins is formed by three different subunits, our 
findings suggest that ThyX proteins have evolved through multimerization of inactive 
monomers. Moreover, because the active-site configuration of ThyX proteins, present 
in many human pathogenic bacteria and of human thymidylate Synthase.  
 
4. F. Esra Önen et al., 14 (2008) potent inhibitors (Thiazolidine derivatives) against 
Thymidylate Synthase (ThyX) was designed, synthesized. Three synthesized series of 
compounds based on a thiazolidine core allowed identification of potent inhibitors of 
thymidylate synthase X. The evaluation of the catalytic activity of the enzyme in the 
presence of these molecules revealed two distinct classes of compounds that inhibit 
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ThyX with submicromolar concentrations, which could lead, after optimization, to 
effective inhibitors with potential biomedical interest.  
 
5. Joshua H. Hunter et al., 15 (2008) Enzyme Kinetics and ligand binding preferences of 
Thymidylate Synthase both ThyX and ThyA in Mycobacterium tuberculosis were 
characterized. Cloning, over expression, and purification, the thymidylate-synthesizing 
ability of ThyA and ThyX gene products were directly confirmed by HPLC analysis of 
reaction products and substrate saturation kinetics were established. 5-Fluoro-29-
deoxyuridine 59-monophosphate (FdUMP) was a potent inhibitor of both ThyA and 
ThyX, offering important clues to double-targeting strategies  
 
6. Martin Kogler et al., 16 (2011) synthesized and Evaluated 5-Substituted 2’-
deoxyuridine Monophosphate Analogues As Inhibitors of Flavin-Dependent 
Thymidylate Synthase in Mycobacterium tuberculosis. Series of 5-substituted 20-
deoxyuridine Monophosphate analogues has been synthesized and evaluated as  
potential inhibitors of mycobacterial ThyX, a novel flavindependent thymidylate 
synthase in Mycobacterium tuberculosis. Their SAR estabilished.   
 
7. M. Paola Costi et al., 17 (2006) developed anti microbial drugs new 1,2-naphthalein 
derivatives have been synthesized and tested against a TS-based biolibrary, including 
human Thymidylate synthase (hTS)  
 
8. Ahmed Haouz et al., 18 (2003) synthesized and structurally analyzed  inhibitors against 
Thymidylate kinase in mycobacterium tuberculosis. The chemical synthesis of new 
compounds designed as inhibitors of Mycobacterium tuberculosis TMP kinase (TMPK) 
is reported. The synthesis concerns TMP analogues modified at the 5-position of the 
thymine ring as well as a novel compound with a six-membered sugar  ring.   
 
9. Jonathan E. Ulmer et al., 19 (2008) functionally analyzed and revealed an extended 
motif of amino acids essential to enzyme activity in M. tuberculosis   
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10. Fre´de´ ric Escartin et al., 20 (2008) studied chromosomal DNA replication in 
Thymidylate Synthase containing organisms. Demonstrate that DNA replication speed 
in bacteria and archaea that contain the low-activity ThyX enzyme is up to 10-fold 
decreased compared with species that contain the catalytically more efficient ThyA. 
 
11.  Hui-Yuan Wang et al., 21 (2008) Pharmacophore modeling and virtual screening for 
designing potential PLK1 inhibitors. The best quantitative Pharmacophoremodel, 
Hypo1, which has the highest correlation coefficient (0.9895), consists of one 
hydrogen bond acceptor, one hydrogen bond donor, one hydrophobic feature, and one 
hydrophobic aliphatic feature.  
 
12. Sugunadevi Sakkiah et al., 22 (2011) Pharmacophore based Virtual Screening, 
molecular docking studies to design potent heat shock protein 90 inhibitors. The best 
hypothesis from Hip-Hop,Hypo1, one hydrogen bond donor (HBD), two hydrogen 
bond acceptors (HBA), and two hydrophobic (H) and structure-based hypothesis, 
SB_Hypo1, one HBA, one HBD and four H features, were generated using Discovery 
Studio and Ligand Scout, respectively.   
 
13. Mohammad Neaz Morshed et al., 23 (2010) Computational approach to the 
identification of novel Aurora-A inhibitors. A three-dimensional common feature 
Pharmacophore model was developed with the HipHop program provided in the 
Catalyst® software package and this model was used as a query for screening the 
databases  
 
Synthesis 
14. Mohit L. Deb and Pulak J. Bhuyan 24 (2005) Uncatalysed Knoevenagel 
condensation in aqueous medium at room temperature. Knoevenagel condensation of 
various aromatic and heteroaromatic aldehydes with active methylene compounds like 
malononitrile, ethyl cyanoacetamide, ethyl cyanoacetate, barbituric acids, Meldrum_s 
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acid, dimedone and pyrazolone proceeds smoothly with stirring in an aqueous 
medium.  
 
15. Khalafi-Nezhad, Ali* and. Hashemi, Aboulghasem 25(2001)  Microwave enhanced 
Knoevenagel Condensation of barbituric acid with aromatic aldehydes on basic 
aIumina. Efficient Knoevenagel condensation of barbituric acid with different 
aromatic aldehydes on basic alumina was performed in a conventional microwave 
ovenin the absence of solvent.  
 
16. Ina Bolz et al., 26 Novel Schiff bases derived from 5-aminobarbituric acid: synthesis 
and solid state structure. Synthesis and characterization of novel Schiff bases with 
multiple binding sites for supramolecular assemblies are presented. For this purpose 
1,3-dimethyl- and 1-butyl-5-aminobarbituric acid are condensed with para-nitro- and 
para-N,N-dimethylaminocinnamaldehyde, respectively 
 
17. Palwinder singh et al., 27 (2005) Microwave synthesis of 5-acyl barbituric acid 
derivatives. Synthesis and characterization of novel Schiff bases with multiple binding 
sites for supramolecular assemblies are presented. For this purpose 1,3-dimethyl- and 
1-butyl-5-aminobarbituric acid are condensed with para-nitro- and para-N,N-
dimethylaminocinnamaldehyde, respectively 
 
18. Kelsey C. Miles et al., 28 The Clauson-Kaas pyrrole synthesis under microwave 
irradiation 10-30 min using water, acetic acid as medium.  
 
19. Da David J. Guerin et al., 29 (1999) Chemical modification of Benzyloxybenzyl-
barbituric acid and its effects on urdpase – synthesized uridine phosphorylase 
inhibitors.   
 
20. James J.-W. Duan et al.,30 (2005) synthesized Non-hydroxamate 5-phenylpyrimidine-
2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-a converting 
enzyme.  
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21. Jie Jack Li et al.,31 (2007) synthesized Quinazolinones and Pyrido[3,4-d]pyrimidin-4-
ones as orally active and Specific Matrix Metalloproteinase-13 inhibitors for the 
treatment of Osteoarthritis.  
 
Invitro activity  
 
22. Clarice Queico at al., 32 (2000) Standartization of Broth Microdilution Method for 
Mycobacterium tuberculosis  
 
23. Ahmet Yilmaz Coban  et al., 33 (2004) Drug susceptibility testing of Mycobacterium 
tuberculosis by the Broth Microdilution method with 7H9 
 
24. Claude Kirimuhuzya et al., 34 The anti-mycobacterial activity of Lantana camara a 
plant traditionally used to treat symptoms of tuberculosis.  
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Aim and Objective 
Aim 
To design and synthesize effective Antitubercular agents against Thymidylate Synthase X 
(ThyX) of Mycobacterium tuberculosis 
The objectives of study include  
1. In-silico design of Thymidylate Synthase (ThyX) inhibitors. 
2. Laboratory synthesis of the designed compounds.   
 5-[(2, 4, 6-trioxotetrahydropyrimidin-5(2H)-ylidene) methyl] furan-2-sulfonic acid. 
 5-{(Z)-[(2, 4, 6-trioxohexahydropyrimidin-5-yl) imino] methyl} furan-2-sulfonic acid. 
 5-[(2, 4, 6-trioxotetrahydropyrimidin-5(2H)-ylidene) methyl] furan-2-sulfonic acid. 
 2-[(2, 4, 6-trioxotetrahydropyrimidin-5(2H)-ylidene) methyl]-4H-imidazole-4-sulfonic 
acid. 
3. Characterization of the above compounds by Infrared Spectroscopy, Nuclear Magnetic 
Resonance and Mass Spectroscopy.  
4. In-vitro Antitubercular activity of synthesized compounds.  
5. Toxicological evaluation.  
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The present study was conducted in according to the following design.  
 
Identification of basic nucleus 
↓ 
Structural Modification of the basic Nucleus 
↓ 
Docking the molecule in the target protein 
↓ 
Optimization of the highly Interacting 
molecule 
↓ 
Top G score compounds selected 
↓ 
Synthesis 
↓ 
Characterization-
Spectroscopy(IR,NMR,MASS) 
↓ 
              In-vitro anti tubercular activity  
↓ 
Toxicological evaluation  
 
  
 
 
MATERIALS  
& 
 METHODS 
 
 
MATERIALS AND METHODS 
 
Department of Pharmaceutical Chemistry  Page 22 
 
4. MATERIALS AND METHODS 
The entire processes comprises of  
• Drug Design 
• Synthesis 
• Characterization 
• In-vitro Antitubercular activity 
• Acute toxicity study 
4.1 DRUG DESIGN  
         A binding interaction between a drug molecule and a target enzyme results in inactivation 
or inhibition of the enzyme. If the protein is a receptor, ligand binding may result in agonism or 
antagonism. Docking is suitable method in the field of drug design to predict.  
4.1.1 Glide Docking 35  
             Using different heterocyclic nucleus large data bases of compounds were prepared and 
docked against Thymidylate Synthase of Mycobacterium tuberculosis using Glide Software 
(Maestro 9.1). Extra precision (XP) scoring function was utilized to rank order the compounds. 
This process was carried out in three steps. 
Identification of basic nucleus  
     Very few compounds have been reported against this Thymidylate Synthase X (ThyX) 
target. Structurally similar molecules with predicted ThyX activity were chosen for synthesis and 
then docked. From the docking result nucleus which has more interaction with the binding site 
are taken for further modifications.  
Design of new ligand   
  Selected basic nucleuses were further substituted with various functional groups and 
more than 2500 newer ligands are synthesized and docked against the Thymidylate Synthase X 
(ThyX). From this high scoring molecules are optimized in the next step.  
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Optimization of the ligand 
Final optimization of the ligand in needed to eliminate the toxic functional groups and minor 
modifications carried out to get the better ligand-target interaction to inhibit the protein. Highest 
scoring 20 ligands are taken regardless of their basic nucleus and their structures are modified by 
inter changing the position of the functional groups, docked in the receptor. More than 200 
compounds are designed in this step and docked against Thymidylate Synthase (ThyX).  For 
optimization of the ligands HIPHOP qualitative study and 2D Similarity searching were used 
Docking score method 
The compounds ranked based on G score which the basic value is obtained by the 
consideration of both rewards and penalties when the molecule interacted with the target.  
 
Rewards 
Lipophilic pair term and fraction of the total protein ligand Vanderwaals energy, 
hydrophobic enclosure reward, hydrophobically packed hydrogen bond, hydrophobically packed 
correlated hydrogen bond, hydrogen bond pair term, electrostatic rewards, sitemap ligand/ 
receptor, Pi and cation, chlorine and bromine, low molecular weight these all are basic 
parameters consider as rewards of the docking score. Rewards values are noted in negative 
values.  
 
Penalty 
Ligand with large hydrophobic contacts and low hydrogen bond scores, exposed 
hydrophobic ligand groups, rotatable bond, similarity these are the basic penalty parameters of 
the docking score. The penalty values should be less in values to indicate best compounds.  
 
4.1.2 HIPHOP generation 36-40 
 Selecting proper orientation of the molecule will have an impact on pharmacophore 
model. Hip-hop is a qualitative method which is used to align a set of molecules based on their 
common chemical features. A minimum of 2 to a maximum of 32 compounds with or without 
activity data is taken as the training set because HIPHOP will consider only common chemical 
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features. Here we taken 6 molecules of known activity to determine 3D spatial arrangements that 
are common to molecules in the training set.  HIPHOP generates feature based 3D-
Pharmacophoric alignment in 3 steps.  
1. A conformation model for each molecule in the training set is generated 
2. Each conformer is examined for the presence of chemical features. 
3. A 3D configuration of chemical features common to input molecules were determined.   
 Catalyst containing a large number of features like, H-bond donor, H-bond acceptor, 
Hydrophobic (both aliphatic and aromatic), Ionizable groups (both positive and negative) which 
can be selected for the HIPHOP hypothesis generation. The features which are present in the 
training set molecules are only selected. For this feature selection knowledge of ligand-receptor 
interaction should be included and the minimum numbers of features are included. After the 
completion of the hypothesis, H-bond donor, H-bond acceptor and negative ionizable groups are 
found as common features in the training set with their inter-feature distances were obtained. 
Based on these features new molecules were screened to find the common features present in it. 
From the large quantity of the designed molecules, 33 were found with same common features as 
in the training set and they were taken for the next step.  
4.1.3 2D similarity searching 
A molecular similarity searching technique based on atom environments, information-
gain-based feature selections present in the molecule. 2D fragment based similarity searching is 
one of the popular technique to find a lead from a large data base of chemical structures and 2D-
fragment based similarity searching found best in terms of hit rate than other methods. The 
molecules having known activity were taken as reference compound and the designed ligands 
which have similar physiochemical features of that reference molecule are screened as 
percentage calculation. We chosen 5-Substituted 2'-deoxyuridine Monophosphate Analogues as 
the reference molecules and the designed molecule contains more similarity were screened.   
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4.2 Mechanism: Antitubercular activity 41, 42 
 
 
 
 
 
                                     
 
Figure 4.1 ThyX Protein and its mechanism 
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Mechanism of Action of Thymidylate Synthase X (ThyX) Activity 
 
 The Folate cycle plays a central role in metabolism. Folate dependent enzymes are 
required for methylation reactions and synthesis of purine and pyrimidine nucleotides and 
many amino acids. 
 
 Many folate cycles are interconnected and the basic model has the qualitative behavior 
seen in folate homeostasis in the cytosol of human cells. 
 
 In DNA synthesis, dividing cells require large quantities of DNA precursor Thymidylate 
(dTMP). In human cells Thymidylate Synthase (ThyA) catalyses the reductive methylation 
of (dUMP) to (dTMP). Using 5, 10-methylene tetrahydrofolate (CH2THF) as a donor of 
one carbon units and as a reductant.  
 
 Formation of dTMP is rate limiting for DNA replication in human cells.  
 
 Differently from human Thymidylate Synthase ThyA, the members of the novel family of 
Thymidylate Synthase ThyX are NADPH oxidases that use flavin adenine nucleoside 
(FAD) to mediate hydride transfer 
 
 Both thyA, thyX catalyses formation of Thymidylate in invitro their reductive mechanism 
is different. thyX catalyses results in formation of THF and not DHF as the product of the 
methylation reaction but virtually nothing is known to rate about how the activity of 
flavin dependent Thymidylate Synthase (ThyX) influences the different folate-dependent 
branches of the bacterial metabolism.  
 
 Mycobacterium and Corneybacterium species contain ThyA and ThyX genes buy due to 
poorly understood why both are maintained in these organisms.   
 
The designed drugs are to inhibit the ThyX protein which is ten times more active in the 
synthesis of DNA than the thyA protein. 
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Final synthesized compounds  
 
 
 
 
N
H
NH O
SO3H
N
O
O
O
 
5-{(Z)-[(2,4,6-trioxohexahydropyrimidin-5-yl)imino]methyl}furan-2-sulfonic acid 
 
N
H
NH
O
O
O
N
N
HO3S
1-[(2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)methyl]-1H-imidazole-2-sulfonic acid
 
 
N
H
NH
O
O
O
N
N
SO3H
 
2-[(2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)methyl]-4H-imidazole-4-sulfonic acid 
 
 
N
H
NH
O
O
O
O
S
O
O
OH
5-[(2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)methyl]furan-2-sulfonic acid
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LIPINSKI RULE 
Drug likeness or the property of a chemical compound having pharmacological or 
biological activity in oral form can be evaluated using Lipinski rule or Rule of five. The rule was 
formulated by Christopher A. Lipinski in 1997, based on the observation that most medication 
drugs are relatively small and lipophilic molecules. Rule of five and other properties are used to 
identify compounds that may be more desirable for high throughput screening and for parallel 
synthesis efforts.  
    The physical properties of the molecules were calculated using Molinspiration molecule 
properties calculator. The results are tabled here.  
 
Compound LogP Mol.Wt TPSA nOHNH nON No of 
rotatable 
bonds 
No of 
violations 
M1 -3.17 
 
286.221 150.305 3 9 2 0 
M2 -3.764 
 
301.236 
 
155.141 
 
3 10 3 0 
M3 -4.145 
 
286.225 
 
154.991 
 
3 10 2 0 
M4 -4.288 
 
286.225 
 
165.848 
 
4 10 2 0 
 
LogP – Partition coefficient 
TPSA – Total Polar Surface Area 
nOHNH – Number of hydrogen donors 
nON – Number of hydrogen acceptors 
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4.3 Synthesis and characterization 
 
4.3.1 SYNTHESIS 24-27, 43, 44, 
All the compounds are synthesized by microwave technique with a domestic microwave 
oven.  
Knoevenagel condensation  
Knoevenagel condensation is condensation of aromatic and heteroaromatic aldehydes 
with active methylene compounds like barbituric acids, malononitrile, ethyl cyanoacetamide, 
ethyl cyanoacetate, Meldrum’s acid, dimedone and pyrazolone proceeds smoothly with stirring 
in an aqueous medium. The reactions occur at room temperature giving excellent yields of the 
products.  
 
Mannich Reaction  
The Mannich reaction is an organic reaction which consists of an amino alkylation of an acidic 
proton placed next to a carbonyl functional group with formaldehyde and ammonia or any 
primary or secondary amine. The final product is a β-amino-carbonyl compound also known as 
a Mannich base 
 
Sulphonation reaction  
Sulphonation, is a method by which sulfonic acids are prepared. Important sulfonation 
procedures include the reaction of aromatic hydrocarbons with sulfuric acid, sulfur trioxide, or 
chlorosulfuric acid, the reaction of organic halogen compounds with inorganic sulfites; and the 
oxidation of certain classes of organic sulfur compounds, particularly thiols or disulfides. 
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REACTANT PROFILE  
Barbituric acid;                                               
                                                      
N
H
NH
O
O O
 
Synonym                       : melonyl urea, 2,4,6-trioxo hexahydro pyrimidine,  
Molecular Formula     : C4H4N2O3, 
 Molecular weight       : 128.09, 
 Melting Point             :  248oC,  
Solubility                     : freely soluble in hot water, Dil.acids, Forms salts with metals, 
Nature                         :  rhomphus solid,  
 
 
Formaldehyde 
                                                               
H
H
O
 
Synonym                      : methylene oxide, formic aldehyde 
Molecular Formula     : CH2O 
 Molecular weight        : 30.03, 
 Melting Point               :  -92oC 
Boiling point                  : -19.5oC  
Solubility                        :  very soluble in water upto 55%, soluble in alcohol, Ether,      
Nature                            :  Liquid 
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Furfural 
                                                     
O
H
O
 
Synonym                             : 2-Furan carboxaldehyde, 2-Furaldehyde 
Molecular Formula            : C5H4O2 
 Molecular weight               : 92.8 
 Melting Point                      :  -36.5oC 
Boiling point                        : 161.8oC  
Solubility                              :  very soluble alcohol, Ether,  
Nature                                   :  colourless oily Liquid, Peculiar odour(Resembling benzaldehyde) 
  
Imidazole;   
                                                             
N
N
H
H
O
 
Synonym                                 : Glyoxaline, 1,3-diazole,  
Molecular Formula               : C4N2H5O 
 Molecular weight                  : 87.02 
 Melting Point                         : 90-91oC,  
Solubility                                 : freely soluble water, alcohol, ether, chloroform, pyridine,  
                                                   Slightly soluble in Pet ether,  
    Nature                                  :  stout prisms,  
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Sulphuric acid 
Synonym                                     : oil of vitriol,  
Molecular Formula                    : H2SO4 
 Molecular weight                       : 98.08 
 Boiling Point                               :  290oC,  
Solubility                                      : freely soluble water.  
Nature                                           :  colourless or slightly coloured viscous liquid, emitting 
                                                          chocking fumes of sulphur trioxide.  
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SYNTHESIS 
N
H
NH
O O
O
OOHC
N
H
NH
O O
O
O
N
H
NH
O O
O
O
SO 3 H
Sulfonation
H 2 SO 4
HNO 3
N
H
NH
O O
O
NO 2
N
H
NH
O O
O
NH 2
N
H
NH
O O
O
N
O
OOHC
Reduction
N
H
NH
O O
O
N
O
SO 3 H
Sulfonation
H 2 SO 4
N N H
C H
O
H
N
H
NH
O O
O
N N
N
H
NH
O O
O
N N
SO 3 H
Sulfonation
H 2 SO 4
N N H
CHO
N
H
NH
O O
O
N
H
N
N
H
NH
O O
O
N
H
N
SO 3 H
Sulfonation
H 2 SO 4
M 1
M 2
M 3 M 4
 
 
Synthesis of compound M1 
Barbituric acid (0.007 M), Furfural (0.009 M), was taken in 250ml beaker. The reaction 
mixture was irradiated on microwave oven at 120oC for 10 mins and then ice cold water added 
and filtered. The completion of the reaction is confirmed by the disappearance of reactants 
(monitored by TLC).  To the obtained product 2-3 ml of sulphuric acid was added and once 
again irradiated on microwave oven at 160oC for 5 mins. With the obtained mixture ice cold 
water was added and filtered and washed with methanol to obtain the product M1.  
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Synthesis of compound M2 
 Barbituric acid (0.007 M) and Nitric acid (0.009 M) were taken in 250ml beaker and 
irradiated on microwave oven at 150oC for 10 mins. The obtained product Nitro barbituric acid 
reduced to amino barbituric acid heating by microwave irradiation and irradiation is continued 
until there is no yellow color in the liquid. The product washed with hydrochloric acid and then 
with water. 
     Amino barbituric acid and furfural (0.009 M) was taken in a 250ml beaker and irradiated 
with microwave at 120oC for 10 min and then ice cold water added and filtered. The completion 
of the reaction is confirmed by the disappearance of reactants (monitored by TLC).  To the 
obtained product 2-3 ml of sulphuric acid was added and once again irradiated on microwave 
oven at 160oC for 10 mins. With the obtained mixture ice cold water was added and filtered and 
washed with methanol to obtain the product compound M2.  
Synthesis of compound M3 
 Barbituric acid (0.007 M), Imidazole(0.009 M) and Formaldehyde (0.009 M) are taken in 
a beaker stirred for 30min at room temperature. The reaction mixture was irradiated on 
microwave oven at 120oC for 10 mins and then ice cold water added and filtered. The 
completion of the reaction is confirmed by the disappearance of reactants (monitored by TLC).  
To the obtained product 2-3 ml of sulphuric acid was added and once again irradiated on 
microwave oven at 160oC for 5 mins. With the obtained mixture ice cold water was added and 
filtered and washed with methanol to obtain the product compound M3.  
Synthesis of compound M4 
Barbituric acid (0.007 M) and Immidazole-2-aldehyde (0.009 M) were taken in 250ml 
beaker. The reaction mixture was irradiated on microwave oven at 120oC for 10mins and then ice 
cold water added and filtered. The completion of the reaction is confirmed by the disappearance 
of reactants (monitored by TLC).  To the obtained product 2-3 ml of sulphuric acid was added 
and once again irradiated on microwave oven at 160oC for 5 mins. The obtained mixture was 
filtered and washed with methanol to obtain the product compound M4.  
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4.3.2 CHARACTERIZATION  
COMPOUND M1  
 
 
N
H
NH
O
O
O
O
S
O
O
OH
5-[(2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)methyl]furan-2-sulfonic acid
Molecular Formula  = C9H6N2O7S
Formula Weight  = 286.21814
Composition  =  C(37.77%) H(2.11%) N(9.79%) O(39.13%) S(11.20%)
Molar Refractivity  = 58.02 ± 0.4 cm3
Molar Volume  = 161.3 ± 3.0 cm3
Parachor  = 480.4 ± 6.0 cm3
Index of Refraction  = 1.638 ± 0.02
Surface Tension  = 78.6 ± 3.0 dyne/cm
Density  = 1.773 ± 0.06 g/cm3
Dielectric Constant  = Not available
Polarizability  = 23.00 ± 0.5 10-24cm3
Monoisotopic Mass  = 285.989571 Da
Nominal Mass  = 286 Da
Average Mass  = 286.2181 Da
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COMPOUND M2 
 
N
H
NH O
SO3H
N
O
O
O
5-{(Z)-[(2,4,6-trioxohexahydropyrimidin-5-yl)imino]methyl}furan-2-sulfonic acid
Molecular Formula  = C9H7N3O7S
Formula Weight  = 301.23278
Composition  =  C(35.88%) H(2.34%) N(13.95%) O(37.18%) S(10.64%)
Molar Refractivity  = 62.63 ± 0.5 cm3
Molar Volume  = 150.6 ± 7.0 cm3
Parachor  = 474.5 ± 8.0 cm3
Index of Refraction  = 1.770 ± 0.05
Surface Tension  = 98.5 ± 7.0 dyne/cm
Density  = 2.00 ± 0.1 g/cm3
Dielectric Constant  = Not available
Polarizability  = 24.83 ± 0.5 10-24cm3
Monoisotopic Mass  = 301.00047 Da
Nominal Mass  = 301 Da
Average Mass  = 301.2328 Da
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COMPOUND M3  
 
 
N
H
NH
O
O
O
N
N
HO3S
1-[(2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)methyl]-1H-imidazole-2-sulfonic acid
Molecular Formula  = C8H6N4O6S
Formula Weight  = 286.22144
Composition  =  C(33.57%) H(2.11%) N(19.57%) O(33.54%) S(11.20%)
Molar Refractivity  = 60.59 ± 0.5 cm3
Molar Volume  = 138.8 ± 7.0 cm3
Parachor  = 450.8 ± 8.0 cm3
Index of Refraction  = 1.823 ± 0.05
Surface Tension  = 111.2 ± 7.0 dyne/cm
Density  = 2.06 ± 0.1 g/cm3
Dielectric Constant  = Not available
Polarizability  = 24.02 ± 0.5 10-24cm3
Monoisotopic Mass  = 286.000804 Da
Nominal Mass  = 286 Da
Average Mass  = 286.2214 Da
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COMPOUND M4 
 
 
N
H
NH
O
O
O
N
N
SO3H
2-[(2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)methyl]-4H-imidazole-4-sulfonic acid
Molecular Formula  = C8H6N4O6S
Formula Weight  = 286.22144
Composition  =  C(33.57%) H(2.11%) N(19.57%) O(33.54%) S(11.20%)
Molar Refractivity  = 59.69 ± 0.5 cm3
Molar Volume  = 132.7 ± 7.0 cm3
Parachor  = 436.4 ± 8.0 cm3
Index of Refraction  = 1.857 ± 0.05
Surface Tension  = 116.9 ± 7.0 dyne/cm
Density  = 2.15 ± 0.1 g/cm3
Dielectric Constant  = Not available
Polarizability  = 23.66 ± 0.5 10-24cm3
Monoisotopic Mass  = 286.000804 Da
Nominal Mass  = 286 Da
Average Mass  = 286.2214 Da
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CHARACTERIZATION 45- 48  
 The synthesized compounds were characterized using following experimental methods. 
1. Infrared spectroscopy (IR) by Perkin-Elmer Spectrometer using KBr pellets. 
2. Nuclear Magnetic Resonance spectroscopy (1H NMR) by 500 MHZ Jeol using 
DMSO. 
3. Mass spectroscopic (MS) by Jeol GC mate.  
4. Melting Point by One side open ended capillary tubes. 
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ANALYTICAL DATA 
COMPOUND M1 
 
 
 
 
 
 
S.No Properties 
1 Molecular formula C9H6N2O7S 
2 Molecular weight 285 
3 Description Black shiny solid 
4 Melting point 284 oC 
5 Percentage yield 83% 
 
IR υcm-1 (KBr):  
3100-3000cm-1 (C-H ), 2854 cm-1(O-H), 1713cm-1 (C=C), 1270-1020cm-1 (C-C), 
1663cm-1(C=O), 910cm-1(S-O), 671cm-1(C-S), 3425cm-1(N-H), 1070cm-1(C-N).  
  1H NMR Data (500 MHz, DMSO-d6)  
δ 2.0 (s, 1H, -OH), 6.2 ( s, 1H, Hetero aromatic C-H), 7.4 ( s, 1H,Hetero aromatic C-H), 
8.01 ( s, 1H, -CH), 10.0 (s, 2H, N-H). 
13C NMR Data (500 MHz, DMSO-d6) 
δ 39.493,39.660, 39.828, 39.995, 40.162, 40.325, 40.495, 67.102, 84.659. 
MASS (m/e value) 
285.99(M+) (9%), 62.16(B) (100%). 
 
N
H
NH
O
O
O
N
N
HO3S
1-[(2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)methyl]-1H-imidazole-2-sulfonic acid
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COMPOUND M2 
 
 
N
H
NH O
SO3H
N
O
O
O
 
5-{(Z)-[(2,4,6-trioxohexahydropyrimidin-5-yl)imino]methyl}furan-2-sulfonic acid 
 
S.No Properties 
1 Molecular formula C9H7N3O7S 
2 Molecular weight 301 
3 Description Grey fine powder 
4 Melting point 276 oC 
5 Percentage yield 76% 
 
IR υcm-1 (KBr):  
1651cm-1 (C=O), 3448cm-1(N-H), 1142cm-1(C-N), 1481cm-1(C-C), 1450cm-1(C=N), 
3024cm-1(C-H), 1296cm-1(C-O), 2900cm-1(O-H), 856cm-1(S-O), 694 cm-1(C-S). 
 
   1H NMR Data (500 MHz, DMSO-d6) 
δ 2.0 (s, 1H, -OH), 3.3 ( s, 1H, C-H), 7.3 ( s, 1H, Aldimine-CH), 6.2 ( s, 2H, ,Hetero 
aromatic CH), 10.0 (s, 2H, N-H).  
13C NMR Data (500 MHz, DMSO-d6) 
δ 39.623, 39.789, 39.956, 40.123, 40.290, 113.235, 150.257, 159.709. 
MASS (m/e value) 
301.28(M+) (7%), 61.78(B) (100%). 
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COMPOUND M3                                                            
N
H
NH
O
O
O
N
N
HO3S
1-[(2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)methyl]-1H-imidazole-2-sulfonic acid
 
 
S.No Properties 
1 Molecular formula C8H6N4O6S 
2 Molecular weight 386 
3 Description Yellow coarse power 
4 Melting point 265 oC 
5 Percentage yield 83% 
 
IR υcm-1 (KBr):  
1690cm-1 (C=O), 3418cm-1(N-H), 1088cm-1(C-N), 1489cm-1(C-C), 1412cm-1(C=N), 
779cm-1(C-C), 3047cm-1(C-H),  2939cm-1(O-H), 895cm-1(S-O).  
 
1H NMR Data (500 MHz, DMSO-d6)  
δ 2.5 (s, 1H, -OH), 6.6 ( s, 1H, C-H), 7.1 ( s, 2H, ,Hetero aromatic C-H),  10.5 (s, 2H, N-
H). 
13C NMR Data (500 MHz, DMSO-d6) 
δ 141.249,  141.332, 152.101, 154.026, 156.149, 158.201. 
 
MASS (m/e value) 
 
286.21(M+) (4%), 65.46(B) (100%). 
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COMPOUND M4 
 
N
H
NH
O
O
O
N
N
SO3H
 
2-[(2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)methyl]-4H-imidazole-4-sulfonic acid 
 
S.No Properties 
1 Molecular formula C8H6N4O6S 
2 Molecular weight 386 
3 Description Sandy yellow fine power 
4 Melting point 272 oC 
5 Percentage yield 52% 
 
 
IR υcm-1 (KBr): 
1690cm-1 (C=O), 3418cm-1(N-H), 1088cm-1(C-N), 1489cm-1(C-C), 1412cm-1(C=N), 
779cm-1(C-C), 3047cm-1(C-H),  2939cm-1(O-H), 895cm-1(S-O).  
 
1H NMR Data (500 MHz, DMSO-d6) 
 δ 2.0 (s, 1H, -OH), 6.6 ( s, 1H, C-H), 7.2 ( s, 1H, ,Hetero aromatic -CH), 7.7 ( s, 1H, 
Hetero aromatic -CH), 10.3 (s, 2H, N-H). 
13C NMR Data (500 MHz, DMSO-d6) 
δ 77.795, 150.249, 151.332, 151.101,164.026, 166.149, 168.201. 
 
MASS (m/e value) 
 
386.21(M+) (3%), 63.34(B) (100%). 
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COMPOUND M1    5-[(2, 4, 6-trioxotetrahydropyrimidin-5(2H)-ylidene) methyl] furan-2-sulfonic acid. 
IR SPECTRA 
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COMPOUND M1 5-[(2, 4, 6-trioxotetrahydropyrimidin-5(2H)-ylidene) methyl] furan-2-sulfonic acid. 
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COMPOUND M1 5-[(2, 4, 6-trioxotetrahydropyrimidin-5(2H)-ylidene) methyl] furan-2-sulfonic acid. 
13C NMR SPECTRA 
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COMPOUND M1 5-[(2, 4, 6-trioxotetrahydropyrimidin-5(2H)-ylidene) methyl] furan-2-sulfonic acid. 
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COMPOUND M2  5-{(Z)-[(2, 4, 6-trioxohexahydropyrimidin-5-yl) imino] methyl} furan-2-sulfonic acid. 
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COMPOUND M2  5-{(Z)-[(2, 4, 6-trioxohexahydropyrimidin-5-yl) imino] methyl} furan-2-sulfonic acid. 
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 COMPOUND M2    5-{(Z)-[(2, 4, 6-trioxohexahydropyrimidin-5-yl) imino] methyl} furan-2-sulfonic acid. 
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COMPOUND M2     5-{(Z)-[(2, 4, 6-trioxohexahydropyrimidin-5-yl) imino] methyl} furan-2-sulfonic acid. 
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COMPOUND M3  5-[(2, 4, 6-trioxotetrahydropyrimidin-5(2H)-ylidene) methyl] furan-2-sulfonic acid. 
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COMPOUND M3  5-[(2, 4, 6-trioxotetrahydropyrimidin-5(2H)-ylidene) methyl] furan-2-sulfonic acid. 
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COMPOUND M3   5-[(2, 4, 6-trioxotetrahydropyrimidin-5(2H)-ylidene) methyl] furan-2-sulfonic acid. 
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COMPOUND M3   5-[(2, 4, 6-trioxotetrahydropyrimidin-5(2H)-ylidene) methyl] furan-2-sulfonic acid. 
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COMPOUND M4        2-[(2, 4, 6-trioxotetrahydropyrimidin-5(2H)-ylidene) methyl]-4H-imidazole-4-sulfonic acid. 
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COMPOUND M4         2-[(2, 4, 6-trioxotetrahydropyrimidin-5(2H)-ylidene) methyl]-4H-imidazole-4-sulfonic acid. 
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COMPOUND M4        2-[(2, 4, 6-trioxotetrahydropyrimidin-5(2H)-ylidene) methyl]-4H-imidazole-4-sulfonic acid. 
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COMPOUND M4 2-[(2, 4, 6-trioxotetrahydropyrimidin-5(2H)-ylidene) methyl]-4H-imidazole-4-sulfonic acid. 
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INVITRO ANTITUBERCULAR STUDY 32-34 
 
Drug susceptibility testing of Mycobacterium tuberculosis by the Broth Micro-
dilution method. 
Inoculum preparation 
 Freshly grown colonies of H37RV from LJ medium were transferred to a tube containing 
3-4 ml PBS and 6 to 9 sterile glass beads. 
 
 Tubes were vigorously agitated on a vortex mixer and clumps were allowed to settle for 
30 mins. 
 
 The supernatant were transferred to a sterile McCartney bottle. 
 
 The supernatant were then adjusted with PBS to equal the turbidity of 0.5 Mc Farland 
standard for use as the standard inoculums in Broth Micro dilution method (BMM). 
 
Turbidity standard for inoculum preparation 
 In microbiology, McFarland standard is used as a reference to adjust the turbidity of 
bacterial suspensions so that the number of bacteria in a specific volume of broth will be 
within a given range 
 
 The standard can be compared visually to a suspension of bacteria in sterile saline or 
nutrient broth. If the bacterial suspension is too turbid, it can be diluted with more 
diluents. If the suspension is less, additional volume of bacterial suspension can be added. 
 
 
 To standardize the inoculums density for a susceptibility test, a BaSO4 turbidity standard, 
equivalent to a 0.5 McFarland standard.  A BaSO4 0.5 McFarland standard may be 
prepared as follows: 
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a) A 0.5-ml aliquot of 0.048 mol/L BaCl2 (1.175% w/v BaCl2. 2H2O) is added to 
99.5 ml of 0.18 mol/L H2SO4 (1% v/v) with constant stirring to maintain a 
suspension. 
 
b) The correct density of the turbidity standard should be verified by using a 
spectrophotometer to determine the absorbance.  The absorbance at 625 nm 
should be 0.008 to 0.10 for the 0.5 McFarland standard. 
 
 
MIC plate’s preparation  
 The plates used were 96-well microtitre plates (TPP) with U-shaped wells.  
 
 The microwells were filled with 0.1 ml of Middlebrook 7H9 broth, supplemented with 
ADC enrichment. 
 
 The stock suspension of each test drug (sterilized in 0.22µm Millipore syringe filter)  was 
diluted by adding Middlebrook 7H9 broth and 0.1 ml volume was dispensed into plates  
and serial dilution for each drug were prepared.  
 
 Each well of the microtiter plate containing 0.1 ml of Middlebrook 7H9 broth and test 
drug was inoculated with 5 µl of standard bacterial suspension. 
 
 A control well with Middlebrook 7H9 broth was inoculated with 5 µl of standard 
bacterial suspension as growth control. 
 
 One bacterial suspension free broth was kept as broth control. 
 
 The plates were sealed and incubated at 37º C for 21 days in a incubator 
 
 The growth of the organism was ascertained by visual observation.  
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 MIC well was identified as the lowest concentration that exhibited no growth by visual 
reading. 
 
 
Minimum Bactericidal Concentration (MBC) tests by recovery plate (31) 
 
 This was taken to be the concentration of the test drug that prevented growth by 99 
percent or greater, compared with the untreated controls.  
 
 Fresh Middle brook 7H11agar in 90-mm plates with division were then prepared, and 
inoculated with a loop full of inocula from the wells and the procedure for incubation 
repeated for up to four weeks. 
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ACUTE TOXICITY STUDY 49 
This acute toxicity study was designed as per OECD guideline for Testing of Chemicals, 
Acute Oral toxicity (Acute Toxic Class method), Guideline 423 
Experimental Procedure 
Healthy adult female Wister Albino mice (3 Nos) were used in this test. Females used 
were weighing between 20-25g, nulliparous and non-pregnant. For all the three animals food, but 
water was withheld overnight prior to dosing.  
The compounds were administered orally to a group of of experimental animals at one of 
the defined dose (2000mg/kg).  
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Observation 
The animals were observed individually after dosing once during the first 30minutes, 
periodically for the 24hrs, with special attention giving during the first 4 hrs, and daily there-
after, for a total of 14 days. The following clinical observations were made and recorded.  
  Toxic designs: All the rats were observed for any toxic signs.  
 
 Pre-terminal deaths: All the rats were observed for any pre-terminal deaths.  
 
 Body weight: Individual body weight was recorded for all the animals once in a week.  
 
 Cage side observation: The faeces colour and consistency, changes in skin and fur, eyes 
and mucous membrane (nasal) of the animal were observed once in a week.   
 
 
  
 
RESULTS  
& 
 DISCUSSION 
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5. Results and Discussion 
The results of the Drug design, Synthesis, Characterization, In-vitro evaluation and 
toxicological study are compiled and presented.   
5.1 DRUG DESIGN 
      Final compounds 
Shortlisted compounds after docking, HIPHOP and 2D similarity searching 
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Structural activity relationship 
 Pyrimidine dione or trione connected with the five membered ring is the 
minimum requirement for the activity. If the five membered ring or 6 membered ring 
replaced by other rings or any other changes in the ring leads to loss of activity.  
 
 Presence of carbonyl group in the 6 membered ring will increase the activity. 
Pyrimidine dione and trione binds more effectively than the pyrimidinone.  
 
 Replacement of 5 membered ring with any other ring will lead to loss of 
activity.  
 
 The 6 membered and 5 membered ring can be connected through one or two 
atoms. If they are more than two atoms apart will terminate the activity. Same time it should 
not be attached like spiro compound. 
 
 Presence of oxygen containing functional groups in the five membered rings is 
must for binding to the receptor. Like COOH, OH, SO3H, PO4, etc.  
 
Ligand – Receptor Interaction 
 Based on the above SAR four compounds were designed and synthesized and they have 
best interaction in the binding site of the receptor. All the four molecules have better interaction 
with the amino acids ARG21, ARG166, SER167, ASP169, HIP 207, and ASN177.  
Lipinski rule  
All the compounds pass the rule of five and there is no violation in the basic properties. It 
proves that our molecule has druglikeness to reach the target site for the biological action. We 
conclude that our molecules have positive nature on ADME character.  
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DOCKING SCORE OF SYNTHESISED COMPOUNDS 
            Compound M1                                                                                                                                                                           Compound M2 
                                                 
                                                    
Compound M3                                                                                                                                                                            Compound M4 
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TABLE : 5.1 
REWARDS 
 
TABLE 5.2                                                                             PENALTIES 
Ligand Penalties HB Penal Phobic Penal RotPenal 
M1 0 0 0 0.095568 
M2 0 0 0 0.174767 
M3 0 0 0 0.095569 
M4 0 0 0 0.095568 
 
Ligand G Score Lipophilic 
EvdW 
PhobEn PhobEn 
HB 
PhobEn 
Pair HB 
H Bond Elect Site map Pi Cat ClBr LowMW 
M1 9.23 -1.14 0 0 0 -4.44 -2.97 0 0 0 -0.5 
M2 9.22 -1.11 0 0 0 -4.78 -2.84 -1.15 0 0 -0.499 
M3 9.15 -1.55 0 0 0 -4.39 -2.85 0 0 0 -0.5 
M4 8.28 -1.50 0 0 0 -3.32 -2.19 -0.03 0 0 -0.5 
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                                   M1                                                                                                                               M2 
                                                  
 
                                     M3                                                                                                                            M4 
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5.2 SYNTHESIS AND CHARACTERIZATION  
Synthesis 
The compound M1 – M4 were prepared from barbituric acid by various steps using 
microwave methods. In M1 and M4, first step barbituric acid condensed with furfural and 2-
Imidazole aldehyde (synthesized by) and the condensed product formed is sulphonated using 
sulphuric acid. M2 is prepared by condensing Uramil (5-Amino barbituric acid) with furfural and 
sulphonating with sulphuric acid. M3 is synthesized by mannich condensation of barbituric acid, 
Imidazole and chloroform and the product is sulphonated with sulphuric acid.     
Characterization   
The synthesized compounds were recrystallized and identified by TLC. The melting point 
of the products were found and are presented uncorrected. The synthesized compounds were 
characterized by using sophisticated instruments like IR, NMR, and MASS spectroscopy.   
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IR SPECTROSCOPY  
IR spectra have been used functional groups present in the synthesized compounds.  
The presence of impurities like the starting materials i.e. aldehyde, amines were ruled out 
by ensuring absence of the functional group of the parent compounds.  
The synthesized compounds showing following specific characteristic stretching and 
bending vibrations.  
TABLE 5.3 
Compound IR Absorption region (cm-1) 
 
M1 
 
3100-3000cm-1 (C-H ), 1675cm-1 (C=C), 1270-1020cm-1 (C-C), 
1725-1660cm-1(C=O), 910-895cm-1(S-O), 800-600cm-1(C-S), 
3500-3300cm-1(N-H), 1070cm-1(C-N). 
 
 
M2 
 
1725-1660cm-1 (C-O), 3500-3300cm-1(N-H), 1070cm-1(C-N), 
1600-1430cm-1(C-C), 1300-735cm-1(C=N), 3100-3000cm-1(C-
H), 1270-1020cm-1(C-O), 2900cm-1(O-H), 910-895cm-1(S-O). 
 
 
M3 
 
1725-1600cm-1 (C=O), 3500-3300cm-1(N-H), 1070cm-1(C-N), 
1600-1430cm-1(C-C)&(C=N), 1300-735cm-1(C-C), 3100-
3000cm-1(C-H),  2900cm-1(O-H), 800-600cm-1(S-O). 
 
 
M4 
 
1725-1600cm-1 (C=O), 3500-3300cm-1(N-H), 1070cm-1(C-N), 
1600-1430cm-1(C-C)&(C=N), 1300-735cm-1(C-C), 3100-
3000cm-1(C-H),  2900cm-1(O-H), 800-600cm-1(S-O). 
 
 
The two important characteristic have been taken as tangible proof for the formation of 
the product.  
 3500-3300cm-1  single peak of the (N-H) stretching. 
 800-600cm-1  single peak corresponds to (S-O) stretching. 
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1H NMR SPECTROSCOPY 
The 1H NMR Spectral data of all the synthesized compounds were in conformity with the 
structure assigned. TABLE 5.4 
 
COMPOUNDS 
 
1H NMR Data (500 MHz, DMSO-d6) 
 
M1 
 
δ 2.0 (s, 1H, -OH), 6.2 ( s, 1H, Hetero aromatic C-H), 7.4 ( s, 1H,Hetero 
aromatic C-H), 8.01 ( s, 1H, -CH), 10.0 (s, 2H, N-H), 
 
M2 
 
δ 2.0 (s, 1H, -OH), 3.3 ( s, 1H, C-H), 7.3 ( s, 1H, Aldimine-CH), 6.2 ( s, 2H, 
,Hetero aromatic CH), 10.0 (s, 2H, N-H), 
 
 
M3 
 
δ 2.5 (s, 1H, -OH), 6.6 ( s, 1H, C-H), 7.1 ( s, 2H, ,Hetero aromatic C-H),  10.5 
(s, 2H, N-H), 
 
M4 
 
δ 2.0 (s, 1H, -OH), 6.6 ( s, 1H, C-H), 7.2 ( s, 1H, ,Hetero aromatic -CH), 7.7  
( s, 1H, ,Hetero aromatic -CH), 10.3 (s, 2H, N-H), 
 
These properties conforms the formation of the products.  
 
13C NMR SPECTROSCOPY 
The 13C NMR Spectra further conforms the structure by giving the carbon skeleton 
present in the synthesized compounds. TABLE 5.5 
Compounds 13C NMR Data (500 MHz, DMSO-d6) 
 
N1 
 
δ 39.493,39.660, 39.828, 39.995, 40.162, 40.325, 40.495, 67.102, 84.659. 
 
 
N2 
 
δ 39.623, 39.789, 39.956, 40.123, 40.290, 113.235, 150.257, 159.709. 
 
 
N3 
 
δ 141.249,  141.332, 152.101, 154.026, 156.149, 158.201. 
 
 
N4 
 
δ 77.795, 150.249, 151.332, 151.101,164.026, 166.149, 168.201. 
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MASS SPECTROMETRY 
All the synthesized compounds are futher structurally conformed by molecular ion (M+) 
of the varying intensities ascertain the molecular weight of the compounds. TABLE 5.6 
 
Compounds 
 
 
Mol. for/ Mol wt  
(calculated) 
 
 
m/e value 
(Relative abundance) 
M1 C9H6N2O7S 
Mol.Wt.286.22 
285.99(M+) (9%), 62.16(B) (100%), 
 
M2 C9H7N3O7S 
Mol.Wt.301.23 
301.28(M+) (7%), 61.78(B) (100%) 
M3 C8H6N4O6S 
Mol.Wt.286.26 
286.21(M+) (4%), 65.46(B) (100%) 
M4 C8H6N4O6S 
Mol.Wt.286.26 
386.21(M+) (3%), 63.34(B) (100%) 
 
The base peaks of the fragments are probably due to  
 
                            
H2N
NH2
O
         or            
N
H
N
 
 
All the above spectral data confirmed the assigned structure of the synthesized 
compounds.  
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5.3 BIOLOGICAL SCREENING 
Invitro antitubercular activity 
The antimycobacterial activities of the synthesized compounds were determined by the 
Broth Microdilution method. The organism used for this study is Mycobacterium tuberculosis 
H37RV.  
All the synthesized compounds showed antibacterial activity to varying degree against 
the organism tested. The organism tested was susceptible to compound M1 and M2 and their 
minimum inhibitory concentration (MIC) was 250µg/ml and 500µg/ml respectively. The data 
pertaining to the activity are presented in the table and the growth of organism was shown in the 
figure.  
Among the synthesized compounds M1 exhibit good activity by minimum inhibition at 
250µg/ml and compound M2 at 500µg/ml. M3 and M4 not shown their Minimum inhibitory 
concentration till 1000µg/ml. the result was perfectly correlated with the results. In the docking 
top scored compound M1 shows best antitubercular activity at lowest concentration 250µg/ml 
than other compounds. Activity scoring followed by the compound M2 at 500µg/ml and M3 and 
M4 doesn’t show any activity.  
 Estimation of MIC by Micro broth dilution technique in MiddleBrook 7H9 broth 
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A – Molecule 1                                        B – Molecule 1 A 
C – Molecule 2                                        D- Molecule 3 
E- Molecule 4                                          F- INH  
G- MTB Control                                      H – Broth control 
 
A row M1.There is no growth in First and Second well: Concentration till 50 microgram per 200 
microliter it was inhibiting the bacterial growth.  
C row M2. It showed activity only in First well; at a concentration of 100 micro liters alone it 
was effective.  
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RESULTS            TABLE 5.7 
 In vitro antimycobacterial assay of molecules Observation after 21days of incubation at 37ºC for Standard strain 
H37Rv 
 100 50 25 12.5 6.25 3.125 1.562 0.7812 0.3906 0.1953 0.09765 0.4883 
Molecule 1 
- - + + + + + + + + + + 
Molecule 2 
- + + + + + + + + + + + 
Molecule 3 + + + + + + + + + + + + 
Molecule 4 + + + + + + + + + + + + 
INH 
- - - - - - - - - - - - 
MTB control + + + + + + + + + + + + 
Broth control 
- - - - - - - - - - - - 
                      (-) – absence of Mycobacterial growth       (+) – presence of Mycobacterial growth 
 Recovery Plates:                                          Standard strain H37RV 
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 TABLE 5.8 
 100 50 25 12.5 6.25 3.125 1.562 0.7812 0.3906 0.1953 0.09765 0.4883 
Molecule 1 
- - + + + + + + + + + + 
Molecule 2 
- + + + + + + + + + + + 
Molecule 3 + + + + + + + + + + + + 
Molecule 4 + + + + + + + + + + + + 
INH 
- - - - - - - - - - - - 
MTB control + + + + + + + + + + + + 
Broth control 
- - - - - - - - - - - - 
                    
(-) – Absence of Mycobacterial growth         (+) – Presence of Mycobacterial growth 
Molecule M
1 100µg/200µl      50µg/200µl                   Molecule M2 100µg/200µl         50µg/200µl  
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                                        5.4 ACUTE TOXICITY STUDIES 
To assess the safety and toxicity of the synthesized compounds, oral acute toxicity were 
carried out in female albino mice as per organization for Economic cooperation and 
Development guidelines 423 (OECD) 
The results of acute toxicity studies shown the synthesized compounds are non toxic and 
did not induce any mortality in the treated mice. The results presented in table.  
Evaluation of Autonomic Nervous System  
It includes changing in salivation, lacrimation, perspiration, piloerection, micturition and 
defection and these were found to be normal.  
Evaluation of central Nervous system 
The animals were observed for ptosis, drowsiness stereotypy, aggression, tremors, 
convulsion, straup’s test, writhing and these were found to be absent. Gait, righting reflex and 
corneal reflex were found to be normal.  
Other interpretations 
Skin, fur, eyes, and bodyweight analysis were found to be normal. Tremors, lethargy, 
diarrhea, and coma were not observed throughout the study period of 14 days.  
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TABLE5.9 
Behavioral and physical observations of synthesized compounds were treated mice for the limit 
test at 2000mg/kg body weight.  
Observation 30min 4hrs 24hrs 48hrs 1 week 2 week 
Straub’s test - - - - - - 
Sedation - - - - - - 
Excitation - - - - - - 
Jumping - - - - - - 
Writhing - - - - - - 
Piloerection - - - - - - 
Stereotypy - - - - - - 
Scratching - - - - - - 
Grooming - - - - - - 
Aggression - - - - - - 
Ptosis - - - - - - 
Exopthalmia - - - - - - 
Loss of righting reflux - - - - - - 
Loss of pinnal reflux - - - - - - 
Loss of corneal reflux - - - - - - 
Salivation Normal Normal Normal Normal Normal Normal 
Lacrimation - - - - - - 
Skin and fur Normal Normal Normal Normal Normal Normal 
Eyes Normal Normal Normal Normal Normal Normal 
Tremors - - - - - - 
Diarrhea - - - - - - 
Coma - - - - - - 
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SUMMARY AND CONCLUSION 
 Candidate molecules were designed based on HipHop (catalyst® software) and docked 
against Thymidylate Synthase X (ThyX) protein using Drug Design Software (Maestro® 
9.1).  
 
 The SAR of high scoring molecules was studied and they are optimized based on the 
synthetic feasibility. 
 
 Four compounds with high G score were shortlisted for the synthesis and they are labeled 
as M1, M2, M3, and M4.   
 
 The structures of the compounds were assigned on the basis of IR, 1H NMR, 13C NMR, 
and MASS data.  
 
 In-vitro Anti tubercular activity – The compounds were screened for antitubercular 
activity by Broth Micro dilution method.   
 
 Of the four compounds M1 and M2 exhibited antitubercular activity; compound M1 
exhibited minimum inhibition at 250µg/ml and M2 at 500µg/ml. 
 
 The docking score of the candidates correlates with the invitro activity of the ligands. 
 
 Toxicological evaluation - The results of acute toxicity studies have shown that the 
synthesized compounds are non toxic and did not induce any mortality at the highest 
OECD guideline dose 2000mg/kg.                               
                 These compounds are attractive strong point to find newer lead compounds which will 
find ultimate use in the treatment of drug resistant tuberculosis. Further these compounds are 
tested for advanced antitubercular assays in in-vitro like Luciferase Reporter Phage Assay 
(LRP), Micro plate Alamar Blue Assay (MABA), Resazurin microtitre Assay (REMA),  
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Serine/Threonine Protein (STP)  Kinase Assay, BACTEC-TB system and  In-vivo assay like 
Balb/C mouse model for CFU and mortality. 
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